Literature DB >> 10723504

Sanctuary sites in HIV-1 infection.

R M Hoetelmans1.   

Abstract

The existence of sanctuary sites for human immunodeficiency virus type 1 (HIV-1) may potentially endanger the efficacy of antiretroviral therapy in the long term and may even make eradication of HIV-1 from the infected body impossible. Potential 'classic' sanctuary sites for HIV-1 are the central nervous system and the testes, but long-lived cell populations (such as macrophages) or latently infected (resting) CD4 cells may also be considered a sanctuary for HIV-1. These potential sanctuary sites, and putative underlying biochemical mechanisms such as the divergent phosphorylation properties of nucleoside reverse transcriptase inhibitors in different cell populations and the affinity of drugs for the multidrug transporter P-glycoprotein, are discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10723504

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  8 in total

1.  Transport of HIV-protease inhibitors across 1 alpha,25di-hydroxy vitamin D3-treated Calu-3 cell monolayers: modulation of P-glycoprotein activity.

Authors:  Jignesh Patel; Dhananjay Pal; Veena Vangal; Mohit Gandhi; Ashim L Mitra
Journal:  Pharm Res       Date:  2002-11       Impact factor: 4.200

2.  Population Modeling Highlights Drug Disposition Differences Between Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in the Blood and Semen.

Authors:  Stephen A Greene; Jingxian Chen; Heather M A Prince; Craig Sykes; Amanda P Schauer; Kimberly Blake; Julie A E Nelson; Cynthia L Gay; Myron S Cohen; Julie B Dumond
Journal:  Clin Pharmacol Ther       Date:  2019-05-31       Impact factor: 6.875

3.  Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients.

Authors:  Jennifer Ford; Marta Boffito; Adrian Wildfire; Andrew Hill; David Back; Saye Khoo; Mark Nelson; Graeme Moyle; Brian Gazzard; Anton Pozniak
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

Review 4.  Clinical implications of CNS penetration of antiretroviral drugs.

Authors:  Heather E Wynn; Richard C Brundage; Courtney V Fletcher
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 5.  Standardized Methods for Enhanced Quality and Comparability of Tuberculous Meningitis Studies.

Authors:  Ben J Marais; Anna D Heemskerk; Suzaan S Marais; Reinout van Crevel; Ursula Rohlwink; Maxine Caws; Graeme Meintjes; Usha K Misra; Nguyen T H Mai; Rovina Ruslami; James A Seddon; Regan Solomons; Ronald van Toorn; Anthony Figaji; Helen McIlleron; Robert Aarnoutse; Johan F Schoeman; Robert J Wilkinson; Guy E Thwaites
Journal:  Clin Infect Dis       Date:  2017-02-15       Impact factor: 9.079

6.  CD32+CD4+ T Cells Sharing B Cell Properties Increase With Simian Immunodeficiency Virus Replication in Lymphoid Tissues.

Authors:  Nicolas Huot; Philippe Rascle; Cyril Planchais; Vanessa Contreras; Caroline Passaes; Roger Le Grand; Anne-Sophie Beignon; Etienne Kornobis; Rachel Legendre; Hugo Varet; Asier Saez-Cirion; Hugo Mouquet; Beatrice Jacquelin; Michaela Müller-Trutwin
Journal:  Front Immunol       Date:  2021-06-16       Impact factor: 7.561

7.  HIV-1 integrase inhibitors are substrates for the multidrug transporter MDR1-P-glycoprotein.

Authors:  Maurizio Cianfriglia; Maria Luisa Dupuis; Agnese Molinari; Antonio Verdoliva; Roberta Costi; Clementina Maria Galluzzo; Mauro Andreotti; Andrea Cara; Roberto Di Santo; Lucia Palmisano
Journal:  Retrovirology       Date:  2007-03-07       Impact factor: 4.602

Review 8.  An insight on promising strategies hoping to cure HIV-1 infection by targeting Rev protein-short review.

Authors:  Sahana Pai; Jayesh Mudgal; B Venkatesh Kamath; K Sreedhara Ranganath Pai
Journal:  Pharmacol Rep       Date:  2021-04-11       Impact factor: 3.024

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.